ICICI Prudential Asset Management Co Ltd Acquires 8,529 Shares of Amgen Inc. $AMGN

ICICI Prudential Asset Management Co Ltd grew its holdings in Amgen Inc. (NASDAQ:AMGN) by 35.9% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 32,267 shares of the medical research company’s stock after purchasing an additional 8,529 shares during the quarter. Amgen makes up 1.0% of ICICI Prudential Asset Management Co Ltd’s portfolio, making the stock its 23rd biggest position. ICICI Prudential Asset Management Co Ltd’s holdings in Amgen were worth $9,106,000 as of its most recent SEC filing.

Several other hedge funds have also recently modified their holdings of AMGN. Brighton Jones LLC lifted its holdings in Amgen by 23.5% during the fourth quarter. Brighton Jones LLC now owns 27,468 shares of the medical research company’s stock worth $7,159,000 after buying an additional 5,226 shares during the period. Sivia Capital Partners LLC raised its position in shares of Amgen by 10.6% in the 2nd quarter. Sivia Capital Partners LLC now owns 1,186 shares of the medical research company’s stock worth $331,000 after acquiring an additional 114 shares in the last quarter. Schnieders Capital Management LLC. raised its position in shares of Amgen by 29.3% in the 2nd quarter. Schnieders Capital Management LLC. now owns 25,859 shares of the medical research company’s stock worth $7,220,000 after acquiring an additional 5,853 shares in the last quarter. Retirement Planning Group LLC lifted its stake in shares of Amgen by 1.4% during the 2nd quarter. Retirement Planning Group LLC now owns 2,752 shares of the medical research company’s stock worth $768,000 after purchasing an additional 39 shares during the last quarter. Finally, Onyx Bridge Wealth Group LLC boosted its position in Amgen by 7.6% during the second quarter. Onyx Bridge Wealth Group LLC now owns 1,538 shares of the medical research company’s stock valued at $429,000 after purchasing an additional 108 shares in the last quarter. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have commented on the stock. TD Cowen reiterated a “buy” rating on shares of Amgen in a report on Wednesday, February 4th. Morgan Stanley boosted their price objective on shares of Amgen from $304.00 to $309.00 and gave the stock an “equal weight” rating in a research note on Wednesday, February 4th. Rothschild & Co Redburn increased their target price on shares of Amgen from $180.00 to $200.00 and gave the company a “sell” rating in a research report on Wednesday. Wells Fargo & Company lifted their price target on shares of Amgen from $325.00 to $375.00 and gave the stock an “equal weight” rating in a report on Thursday. Finally, Cantor Fitzgerald upped their price target on Amgen from $315.00 to $350.00 and gave the stock a “neutral” rating in a research report on Wednesday, February 4th. One analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating, ten have assigned a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, Amgen currently has an average rating of “Moderate Buy” and an average price target of $345.16.

Amgen Price Performance

Shares of AMGN opened at $375.50 on Friday. The company has a debt-to-equity ratio of 5.78, a current ratio of 1.14 and a quick ratio of 0.90. The company’s fifty day moving average price is $342.07 and its 200-day moving average price is $315.70. Amgen Inc. has a 1-year low of $261.43 and a 1-year high of $385.12. The firm has a market capitalization of $202.42 billion, a PE ratio of 26.39, a price-to-earnings-growth ratio of 3.89 and a beta of 0.46.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Tuesday, February 3rd. The medical research company reported $5.29 EPS for the quarter, topping analysts’ consensus estimates of $4.76 by $0.53. The company had revenue of $9.87 billion during the quarter, compared to analysts’ expectations of $9.46 billion. Amgen had a return on equity of 148.37% and a net margin of 20.98%.The firm’s revenue was up 8.6% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $5.31 EPS. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. On average, equities research analysts predict that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, March 6th. Investors of record on Friday, February 13th will be given a $2.52 dividend. This is an increase from Amgen’s previous quarterly dividend of $2.38. This represents a $10.08 dividend on an annualized basis and a yield of 2.7%. The ex-dividend date is Friday, February 13th. Amgen’s payout ratio is currently 70.84%.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.